Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study.
about
Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials.Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer.Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity.
P2860
Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Innovative sequence of docetax ...... lung cancer: a phase I study.
@ast
Innovative sequence of docetax ...... lung cancer: a phase I study.
@en
type
label
Innovative sequence of docetax ...... lung cancer: a phase I study.
@ast
Innovative sequence of docetax ...... lung cancer: a phase I study.
@en
prefLabel
Innovative sequence of docetax ...... lung cancer: a phase I study.
@ast
Innovative sequence of docetax ...... lung cancer: a phase I study.
@en
P2093
P1433
P1476
Innovative sequence of docetax ...... lung cancer: a phase I study.
@en
P2093
Anna Tesei
Dino Amadori
Giovanni Luca Frassineti
Ida Colantonio
Manuela Monti
Toni Ibrahim
Wainer Zoli
P304
P356
10.1016/J.LUNGCAN.2004.06.011
P577
2005-02-01T00:00:00Z